已核实 DOI PubMed 相关产品: 0

Synthesis and anti-tumor activity of EF24 analogues as IKKβ inhibitors

Journal 2017 · IF 4.519 · 发表于 2017 年 12 月 7 日
作者: Rong Jin,Qiuxiang Chen,Song Yao,Encheng Bai,Weitao Fu,Ledan Wang,Jiabing Wang,Xiaojing Du,Tao Wei,Haineng Xu,Chengxi Jiang,Peihong Qiu,Jianzhang Wu,Wulan Li,Guang Liang
阅读全文 在 PubMed 查看

摘要

EF24 is an IKKβ inhibitor (IC 50 : 72 μM) containing various anti-tumor activities. In this study, a series of EF24 analogs targeting IKKβ were designed and synthesized. Several IKKβ inhibitors with better activities than EF24 were screened out and B3 showed best IKKβ inhibitory (IC 50 : 6.6 μM). Molecular docking and dynamic simulation experiments further confirmed this inhibitory effect. B3 obviously suppressed the viability of Hela229, A549, SGC-7901 and MGC-803 cells. Then, in SGC-7901 and MGC-803 cells, B3 blocked the NF-κB signal pathway by inhibiting IKKβ phosphorylation, and followed arrested the cell cycle at G2/M phase by suppressing the Cyclin B1 and Cdc2 p34 expression, induced the cell apoptosis by down-regulating Bcl-2 protein and up-regulating cleaved-caspase3. Moreover, B3 significantly reduced tumor growth and suppressed the IKKβ-NF-κB signal pathway in SGC-7901 xenograft model. In total, this study present a potential IKKβ inhibitor as anti-tumor precursor.